ST交昂(600530) - 2018 Q1 - 季度财报

Financial Performance - Operating revenue increased by 4.46% to CNY 81,865,683.22 year-on-year[7] - Net profit attributable to shareholders decreased by 8.07% to CNY 30,967,251.07 compared to the same period last year[7] - Net profit excluding non-recurring gains and losses increased by 121.58% to CNY 16,239,478.90[7] - Total revenue for Q1 2018 was CNY 83,632,346.22, an increase of 4.8% compared to CNY 80,255,172.89 in the same period last year[33] - Operating income for the same period was CNY 81,865,683.22, up from CNY 78,367,237.62, reflecting a growth of 6.4%[33] - Net profit for Q1 2018 reached CNY 37,029,982.39, up 40.8% from CNY 26,270,242.86 in the same period last year[38] - The company reported a total profit of CNY 40,885,446.16 for Q1 2018, an increase of 21.6% from CNY 33,629,343.88 in Q1 2017[38] - Basic earnings per share for Q1 2018 were CNY 0.047, compared to CNY 0.034 in the previous year, representing a growth of 38.2%[38] Asset and Liability Changes - Total assets decreased by 7.01% to CNY 2,102,107,965.20 compared to the end of the previous year[7] - Total current assets decreased from ¥396,118,720.41 at the beginning of the year to ¥299,103,973.87 by March 31, 2018[25] - Non-current assets totaled CNY 1,606,912,800.52, down from CNY 1,656,924,026.38, indicating a decrease of 3.1%[30] - Total assets amounted to CNY 2,123,498,439.62, a decline from CNY 2,204,201,273.31, reflecting a decrease of 3.7%[31] - Current liabilities decreased to CNY 383,889,413.58 from CNY 436,268,369.28, showing a reduction of 12.0%[30] - Total liabilities were CNY 457,395,638.49, down from CNY 526,113,059.28, indicating a decrease of 13.1%[31] - Owner's equity totaled CNY 1,666,102,801.13, slightly down from CNY 1,678,088,214.03, a decrease of 0.7%[31] - Deferred income tax liabilities were CNY 68,926,224.91, down from CNY 85,264,690.00, reflecting a decrease of 19.1%[31] Cash Flow Analysis - Cash flow from operating activities showed a net outflow of CNY 8,606,885.71, an improvement from the previous year's outflow of CNY 9,086,093.97[7] - The net cash flow from operating activities was -8,606,885.71 RMB, compared to -9,086,093.97 RMB in the previous period, indicating a slight improvement[41] - Total cash inflow from investment activities was 29,044,631.18 RMB, down from 109,236,094.34 RMB in the previous period[42] - The net cash flow from investment activities was 8,059,588.98 RMB, significantly lower than 96,720,021.74 RMB in the previous period[42] - Cash inflow from financing activities totaled 100,000,000.00 RMB, compared to 235,000,000.00 RMB in the previous period[42] - The net cash flow from financing activities was -114,688,171.25 RMB, a decrease from 59,109,764.18 RMB in the previous period[42] - The ending balance of cash and cash equivalents was 136,838,886.83 RMB, down from 285,613,364.33 RMB in the previous period[42] - The company's cash and cash equivalents dropped from ¥252,666,512.56 at the beginning of the year to ¥137,028,886.83 by March 31, 2018[25] - Cash and cash equivalents decreased to CNY 52,880,690.96 from CNY 148,426,993.47, a significant decline of 64.4%[29] Investment and Capital Expenditure - Construction in progress rose by 89.71% to CNY 43,635,807.50 due to ongoing investments in new factory projects[12] - Prepayments increased by 74.48% to CNY 6,245,252.40 as subsidiaries received advance payments[12] - The company approved a non-public issuance plan and related proposals during the sixth board meeting and 2015 annual shareholders' meeting, with adjustments being made due to new regulations[18] - A new production facility is being established in Shanghai with an investment of approximately ¥70 million, expected to be completed by the end of June 2017, pending government approvals[18] - The company plans to increase capital in its wholly-owned subsidiary, Shanghai Jiao Tong University Angli Life Science Technology Development Co., Ltd., with a total investment of ¥70 million[18] - The company announced a major asset restructuring plan to acquire Tonghua Wan Tong Pharmaceutical Co., Ltd., aiming to enhance competitive strength and expand development space[19] Shareholder Activities - As of January 8, 2018, a shareholder group acquired 39,000,072 shares, representing 5% of the total share capital, and plans to further increase their holdings by up to 10%[20] - Company executives have also announced plans to buy back shares, with a total of 800,000 shares purchased, accounting for 0.102% of the total share capital[21] Expense Management - Financial expenses increased by 47.93% to CNY 9,428,473.31 compared to the previous period[15] - Tax expenses decreased by 45.60% to CNY 1,151,714.20 year-on-year[15] - Sales expenses increased to CNY 1,794,750.16 in Q1 2018 from CNY 110,647.35 in the previous year, indicating a significant rise[37] - Management expenses decreased to CNY 7,930,912.83 from CNY 10,640,293.22, showing a reduction of 25.5%[37] - The company experienced a tax expense of CNY 3,855,463.77 in Q1 2018, compared to CNY 7,359,101.02 in the previous year, indicating a decrease of 47.6%[38]